ORIC Pharmaceuticals Business Model Canvas

Clinical research organizations deliver trial operations, monitoring, data management and global site activation, enabling ORIC to run complex oncology studies. CRO partnerships scale multi-center trials efficiently; the global CRO market was roughly $70 billion in 2024, reflecting broad capacity. Robust CRO quality systems underpin regulatory compliance and patient safety. Their extensive geographic footprint accelerates enrollment in niche indications.

Academic collaborations supply resistant models and translational expertise; pharma alliances share late‑stage risk and commercialization; CROs, CDx and CDMOs provide trial execution, patient selection and GMP supply to de‑risk development and scale launch.

Design biomarker-enriched Phase 1/2 trials (cohorts typically 20–40 patients) to demonstrate proof-of-concept and enable rapid go/no-go decisions. Optimize dose, schedule and combination regimens through adaptive designs and PK/PD modeling. Manage sites, enrollment and centralized safety monitoring to meet projected 12–18 month cohort timelines. Generate high-quality, regulatory-grade datasets for IND/IMPD and agency interactions.

Use genomics and CRISPR/RNAi screens (~18,000 genes) to find resistance pathways and build IP around validated hits.

Advance leads via iterative medicinal chemistry, aiming for 10–20% preclinical-to-IND success (2024 benchmarks) with ADME/Tox and GMP-ready CMC.

Run biomarker-driven Phase 1/2 cohorts (20–40 pts) with 12–18 month cohort timelines and pursue Fast Track/Breakthrough interactions (ORIC, NASDAQ: ORIC, active 2024).

Patents on compounds, compositions and methods form the core of ORIC Pharmaceuticals intellectual property, granting statutory protection with typical patent terms of up to 20 years. Filing strategies extend exclusivity across indications and geographies and can be complemented by regulatory exclusivities of up to five years in many jurisdictions. Trade secrets preserve proprietary assays and analytics, while freedom-to-operate analyses de-risk development and commercialization pathways.

Experienced chemists, biologists and clinicians with resistance-biology focus drive target validation; cross-functional teams cut development time 30–50% (McKinsey 2024). Proprietary resistance models, biomarkers and aggregated datasets improve translational predictivity; >70% strategic decisions are data-driven. Patents, trade secrets and investigator/regulatory networks support expedited pathways (FDA priority review 6m, 2024).

ORIC assets are engineered for use alongside targeted agents and immuno-oncology drugs, addressing a market where over 50% of oncology trials in 2024 test combinations and the global oncology therapeutics market exceeded $200B in 2024; synergistic combinations can delay resistance emergence, combination-ready safety profiles are prioritized to enable co-dosing, and this approach broadens market adoption and payer uptake.

ORIC targets resistance mechanisms to restore/extend oncology efficacy, advancing multiple Phase 1/2 programs in 2024 to deliver longer durable responses. Companion diagnostics (50+ FDA-cleared in 2024) enable 2–3x higher response rates in biomarker-selected cohorts, shrinking trial sizes and improving success odds. Oral, combination-ready small molecules align with >50% of 2024 oncology trials testing combos and a >$200B 2024 market.

Advisory boards of 8–12 key opinion leaders inform study design and endpoints to align trials with regulatory and payer expectations. KOLs commonly accelerate site activation by ~20% and drive publication strategy and authorship networks. Their endorsement builds credibility with investigators and payers, improving enrollment and retention. Ongoing dialogues with KOLs refine clinical positioning across multi‑site programs.

Engage oncologists via CME, ASCO (~40,000 attendees) and KOL advisory boards (8–12 members) to speed site activation ~20% and drive adoption. Provide biomarker-guided algorithms and medical support; only 3–5% of adult cancer patients enroll in trials (2024). Partner with advocacy groups to expand enrollment and provide financial/side-effect support. Early HE modeling and RWE sharing shape payer agreements.

Present data at ASCO (≈30–40k attendees), ESMO (≈25k) and AACR (≈20k) and publish in peer-reviewed journals to build scientific credibility that drives uptake; peer-reviewed publication increases prescribing adoption by as much as 15–25% in oncology launches. KOL discussions and advisory boards amplify messages across networks of >1,000 specialists. Timed disclosures tied to IND/phase milestones optimize market impact and investor confidence.

ORIC targets 71 NCI centers with a focused field force, prioritizing high‑volume hubs to drive uptake. Leverages CDx lab networks in a $8.2B 2024 market to ID patients and integrate EMR ordering. Scientific channels (ASCO 30–40k, ESMO 25k) plus publications/KOLs scale adoption and referral flow.

With 1.96 million new US cancer cases estimated in 2024, many patients with progressed, treatment‑resistant disease urgently seek effective later‑line options; oral, tolerable regimens are strongly preferred to preserve quality of life. Access and financial support—manufacturer patient assistance and insurance navigation—are critical, and advocacy groups such as the American Cancer Society play key roles in coordinating care and resources.

Medical oncologists drive prescribing for 1.96M new US cancer cases (2024), prioritizing biomarker-led, tolerable later-line therapies. Institutions (≈6,000 US hospitals, 71 NCI centers) and P&T committees require robust outcomes and budget impact. Payers (Medicare ≈64M beneficiaries) demand cost-effectiveness, RWE and utilization controls for coverage.

Preparation of INDs/NDAs and ongoing compliance consume multi‑million dollars—IND/NDA prep often runs $2–10M and US PDUFA user fee for 2024 was about $3.2M—while audits, pharmacovigilance and safety database maintenance typically cost $0.5–3M annually; consultancy and legal fees can add $0.5–2M; global filings (EU, UK, Japan, China) can multiply total regulatory spend 2–5x.

R&D/clinical and CMC dominate costs: Phase1 $1–5M, Phase2 $10–40M, CMC 20–30% pre‑IND with $1–10M scale‑up. Regulatory & safety ~$0.5–10M/yr plus PDUFA $3.2M (2024). Commercial prep $10–50M; G&A ~20–25% of operating spend.

Tiered royalties on net sales, commonly structured in the 5–20% range across industry licensing deals, provide ORIC with recurring revenue when partners commercialize candidates. These royalties can escalate with volume or new indications via step-ups tied to sales thresholds. Patent-protected products typically deliver 10+ years of post-approval cash flow, underpinning steady-state profitability.

ORIC reported zero product revenue in 2024; future sales depend on biomarker-selected oncology indications and line placement with EU/APAC expansion upside. Partner deals (median upfront ~$40M in 2024) plus staged milestones and tiered royalties (typical 5–20%) and selective co-promotion/profit share provide de‑risked, recurring economics. Early R&D is supported by NIH SBIR/STTR (Phase I $275,000; Phase II $1.75M) and fee‑for‑service.